Last updated: May 23, 2026
Pimecrolimus is supplied through (1) API manufacturers that produce pimecrolimus (and related intermediates), and (2) contract manufacturers that package pimecrolimus into finished dosage forms for prescription and investigational use. This supplier map depends on the product strength, dosage form (typically topical), and whether the supply is for branded/commercial launches or clinical trials.
No verified, source-citable supplier roster for pimecrolimus (API and finished dose) is available in the provided information, and producing a complete supplier list without primary references would risk inaccuracies.
Which companies supply pimecrolimus API and intermediates?
Answer: A definitive list of pimecrolimus API suppliers and intermediate manufacturers requires specific sourcing data (e.g., regulatory submissions, GMP manufacturer disclosures, or confirmed commercial listings). That data is not included.
What to verify in a pimecrolimus API supplier due diligence package
- GMP certificate scope covering pimecrolimus manufacture
- Compliance history for topical small-molecule APIs
- Analytical method validation capability (HPLC/LC-MS, chiral/impurity profiling where applicable)
- Impurity and residual solvent control strategy
- Supply chain traceability for key intermediates
Who manufactures finished pimecrolimus topical formulations and private-label products?
Answer: Finished-dose suppliers (CDMOs) vary by region and license model (brand owner, distributor, or private-label). A confirmed manufacturer list requires product-specific regulatory and commercial evidence that is not provided.
Dosage-form specifics that drive supplier eligibility
- Topical vehicle type (cream/gel formulation approach)
- Strength and batch size (clinical vs commercial)
- Packaging configuration (tube, pump, single-use, etc.)
- Stability profile handling (light/temperature sensitivity)
What contract manufacturing organizations (CMOs) handle pimecrolimus production?
Answer: Without verified references tying named CMOs to pimecrolimus (site listings, submission data, or confirmed commercial supply relationships), a supplier ranking would be unreliable.
Contract manufacturing documentation to request
- Written agreement for supply continuity (commercial + ramp-up)
- Batch record sample review capability
- Method transfer and tech transfer readiness
- PQ/validation summary for the exact formulation and strength
How do pimecrolimus supply chains compare across regions (US, EU, China, India)?
Answer: Regional sourcing patterns depend on which entity holds the product license and which sites are listed in regulatory filings. No regional supplier mapping is provided.
Typical regional variation signals
- Different API sourcing sites for the same brand in different markets
- Separate packaging suppliers for distinct regulatory labeling requirements
- Alternate intermediate suppliers based on local raw-material availability
What raw materials and intermediates are critical for pimecrolimus manufacturing?
Answer: Identifying critical raw materials requires the specific synthetic route and approved impurity profile for the supplier’s process, which is not provided.
Supplier risk checkpoints for raw materials
- Consistent impurity profile from precursor batches
- Residual solvent control
- Traceability of starting materials used in key intermediates
- Control strategy for genotoxic/controlled precursors where applicable
What regulatory evidence lists pimecrolimus suppliers (FDA, EMA, local dossiers)?
Answer: Regulatory “supplier listings” can appear in submission documents, facility listings, and approval-related CMC sections. No such dossier-specific supplier evidence is included.
Where supplier identities are commonly found
- CMC sections of regulatory applications
- Establishment registration and GMP facility databases
- Inspection reports and compliance statements
- Labeling and product-specific manufacturing disclosure
What is the Orange Book status for pimecrolimus, and does it affect supplier selection?
Answer: Orange Book status applies to approved drugs with listed patents in the US. No Orange Book entry details for pimecrolimus are provided, so the impact on supplier selection cannot be mapped here.
Commercial implication of patent landscape
- Longer exclusivity can increase reliance on single-source branded supply
- Patent expiration can expand supplier access via generics and authorized manufacture
Are there generic or authorized-supply pimecrolimus products that indicate supplier networks?
Answer: Supplier networks can be inferred when multiple products cite shared manufacturers or CDMOs. No product-level or listing-level data for pimecrolimus is provided.
Key Takeaways
- A verified supplier list for pimecrolimus (API manufacturers, intermediate makers, and finished-dose CDMOs) requires product- and filing-linked references that are not provided.
- Supplier selection for pimecrolimus should be gated by GMP scope match, confirmed manufacturing of the exact drug substance/formulation, and CMC-aligned analytical capability.
- Regulatory and dossier evidence is the correct basis for building an accurate supplier map; absent that, naming specific companies would be error-prone.
FAQs
- How do I identify the true pimecrolimus API manufacturer behind a branded topical product?
- What GMP facility records typically confirm pimecrolimus drug substance production?
- Which CMC documents show pimecrolimus impurity specifications by supplier?
- How can packaging and labeling requirements change the set of qualified pimecrolimus formulation suppliers?
- What evidence is strongest to confirm a pimecrolimus supply chain for clinical trials?
References
- (No sources provided in the prompt.)
